Aug
12
2025
On demand

Commercialization of CAR-T therapy in New Zealand: clinical insights & scalable manufacturing

Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Sponsor
Commercialization of CAR-T therapy in New Zealand: clinical insights & scalable manufacturing

A pioneering CAR-T program is redefining treatment for relapsed/refractory B-cell non-Hodgkin lymphoma. Join leading scientists as they share exclusive data and lessons learned from New Zealand’s first CD19-specific CAR-T cell therapy program. Explore how a third-generation CAR design with a TLR2 domain is delivering promising clinical outcomes–while being manufactured on an automated, closed system platform.

This webinar will discuss the scalable manufacturing of CAR-T cells and provide clinical data and guidance on achieving commercialization of CAR-T in New Zealand.

  • Discover how the ENABLE-1 Phase 1 trial achieved a 53% complete response rate with low incidence of CRS and neurotoxicity, with most patients managed in outpatient settings
  • Learn how CAR-T cells were successfully manufactured using an adapted process on the Cocoon® Platform, including insights from the dose expansion cohort where 7 of 9 patients received product manufactured in this platform
  • Get a first look at the ENABLE-2 Phase 2 trial and the roadmap to commercial-scale manufacturing in New Zealand, including the development of a facility in Christchurch, NZ
Tamara Laskowski
Tamara Laskowski
Senior Director, Program Development and Translation at Lonza

Dr Tamara Laskowski is the Senior Director and Head of Clinical & Process Development at Lonza . In her role, she supports the development of novel T cell and NK cell therapies targeting solid and hematological malignancies and the transition of processes from pre-clinical stage into clinical manufacturing. Moreover, Dr Laskowski oversees the implementation of enhanced analytics for monitoring critical attributes associated with product fitness and function. Dr Laskowski received a doctorate degree in the fields of Human Molecular Genetics and Immunology from the University of Texas Health Science Center at Houston where her work focused on targeted genome editing of patient stem cells to correct genetic mutations linked to immune disorders. Dr Laskowski was awarded a fellowship to the National Science Foundation Innovation Corps program dedicated to training scientists to develop strategies for expanding the economic and societal benefits of innovative ideas that have commercialization potential. She was the sole recipient of an award for outstanding performance upon completion of the program.

Laurence Cooper
Laurence Cooper
Director at BioOra

Trained as a physician scientist, Laurence has had leadership positions in academia and industry in cancer, gene therapy, immunotherapy, and infectious disease. He has developed and implemented numerous cellular therapies translating ideas and technologies from bench to bedside and back. Laurence has helped start and fund multiple companies inside and outside of biotechnology. He has been a CEO for a public company and held multiple academic appointments including Pediatrics, Oncology, and Immunology, Chief Bone Marrow Transplantation, and was a tenured professor at the University of Texas MD Anderson Cancer Center and on faculty at UTHealth Houston Graduate School. Among his current appointments, he is on the Board of BioOra which is commercializing CD19-specific CAR-T manufactured using the Cocoon Platform. He is a board-certified physician and is the author of numerous papers, books, and patents.